维生素C、氢化可的松与硫胺素联合对比单用氢化可的松对脓毒性休克患者无升压药支持生存时间的影响:VITAMINS随机临床试验
VITAMINS多中心、开放标签随机临床试验在澳大利亚、新西兰和巴西的10个ICU纳入216例符合Sepsis-3定义的脓毒性休克患者,比较静脉维生素C(1.5 g每6小时)、氢化可的松(50 mg每6小时)和硫胺素(200 mg每12小时)联合方案与单用氢化可的松(50 mg每6小时)直至休克缓解或最多10天。主要终点7天内无升压药支持的生存时间在干预组为122.1小时,对照组为124.6小时,配对差值中位数-0.6小时(95%CI -8.3至7.2小时;P=0.83),无统计学显著差异。10项预设次要终点中9项无显著差异;90天死亡率干预组28.6%(30/105) vs 对照组24.5%(25/102),HR 1.18(95%CI 0.69-2.00)。未报告严重不良事件。
要点
- 在脓毒性休克患者中,维生素C+氢化可的松+硫胺素联合方案对比单用氢化可的松,7天内无升压药支持的生存时间无显著差异(122.1 vs 124.6小时;配对差值中位数-0.6小时,95%CI -8.3至7.2;P=0.83)。
- 90天死亡率干预组28.6%(30/105) vs 对照组24.5%(25/102),HR 1.18(95%CI 0.69-2.00),未达统计学显著。
- 10项预设次要终点中9项无统计学显著差异。
- 未报告严重不良事件。
- 作者认为,与单用静脉氢化可的松相比,静脉维生素C、氢化可的松和硫胺素联合治疗并未导致脓毒性休克更快速缓解。
适用人群与场景
- 符合Sepsis-3定义的脓毒性休克成人患者,来自澳大利亚、新西兰和巴西的10个ICU。
- 纳入216例随机分组,其中211例提供知情同意并完成主要终点测量;平均年龄61.7岁(SD 15.0),男性133例(63%)。
诊断标准与关键阈值
- 脓毒性休克诊断采用Sepsis-3定义。
处置流程与药物剂量
- 干预组(n=109):静脉维生素C 1.5 g每6小时 + 氢化可的松50 mg每6小时 + 硫胺素200 mg每12小时,直至休克缓解或最多10天。
- 对照组(n=107):静脉氢化可的松50 mg每6小时单用,直至休克缓解或最多10天。
研究设计与关键结果
- 研究类型:多中心、开放标签、随机临床试验,在澳大利亚、新西兰和巴西的10个ICU进行,纳入216例脓毒性休克患者,随机分为干预组(n=109)和对照组(n=107)。
- 主要终点:7天内无升压药支持的生存时间,干预组122.1小时(IQR 76.3-145.4) vs 对照组124.6小时(IQR 82.1-147.0),配对差值中位数-0.6小时(95%CI -8.3至7.2小时;P=0.83)。
- 次要终点:10项预设次要终点中9项无统计学显著差异。
- 90天死亡率:干预组30/105(28.6%) vs 对照组25/102(24.5%),HR 1.18(95%CI 0.69-2.00)。
- 不良事件:未报告严重不良事件。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于脓毒性休克患者,作者认为静脉维生素C、氢化可的松和硫胺素联合治疗对比单用静脉氢化可的松并未导致更快速的休克缓解;该结果不支持将此联合方案用于加速脓毒性休克缓解。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is unclear whether vitamin C, hydrocortisone, and thiamine are more effective than hydrocortisone alone in expediting resolution of septic shock.
OBJECTIVE: To determine whether the combination of vitamin C, hydrocortisone, and thiamine, compared with hydrocortisone alone, improves the duration of time alive and free of vasopressor administration in patients with septic shock.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, open-label, randomized clinical trial conducted in 10 intensive care units in Australia, New Zealand, and Brazil that recruited 216 patients fulfilling the Sepsis-3 definition of septic shock. The first patient was enrolled on May 8, 2018, and the last on July 9, 2019. The final date of follow-up was October 6, 2019.
INTERVENTIONS: Patients were randomized to the intervention group (n = 109), consisting of intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours), or to the control group (n = 107), consisting of intravenous hydrocortisone (50 mg every 6 hours) alone until shock resolution or up to 10 days.
MAIN OUTCOMES AND MEASURES: The primary trial outcome was duration of time alive and free of vasopressor administration up to day 7. Ten secondary outcomes were prespecified, including 90-day mortality.
RESULTS: Among 216 patients who were randomized, 211 provided consent and completed the primary outcome measurement (mean age, 61.7 years [SD, 15.0]; 133 men [63%]). Time alive and vasopressor free up to day 7 was 122.1 hours (interquartile range [IQR], 76.3-145.4 hours) in the intervention group and 124.6 hours (IQR, 82.1-147.0 hours) in the control group; the median of all paired differences was -0.6 hours (95% CI, -8.3 to 7.2 hours; P = .83). Of 10 prespecified secondary outcomes, 9 showed no statistically significant difference. Ninety-day mortality was 30/105 (28.6%) in the intervention group and 25/102 (24.5%) in the control group (hazard ratio, 1.18; 95% CI, 0.69-2.00). No serious adverse events were reported.
CONCLUSIONS AND RELEVANCE: In patients with septic shock, treatment with intravenous vitamin C, hydrocortisone, and thiamine, compared with intravenous hydrocortisone alone, did not significantly improve the duration of time alive and free of vasopressor administration over 7 days. The finding suggests that treatment with intravenous vitamin C, hydrocortisone, and thiamine does not lead to a more rapid resolution of septic shock compared with intravenous hydrocortisone alone.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03333278.
参考来源
- Fujii T, Luethi N, Young PJ, et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial. JAMA. 2020. PMID: 31950979. doi:10.1001/jama.2019.22176
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。